Oligonucleotide CDMO Market’s CAGR of 8.9%: Key Players According to a newly published market research report by 24LifeSciences, global oligonucleotide process development and manufacturing market was valued at USD 1.14 billion in 2024 and is projected to reach USD 2.04 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.9% during the forecast period 2025-2031. Oligonucleotides, which are short, single-stranded DNA or RNA molecules typically consisting of 20 to 30 nucleotides, play crucial roles in antisense therapy, gene silencing, and as primers or probes in molecular biology. The manufacturing process involves sophisticated techniques including solid-phase synthesis using phosphoramidite chemistry, followed by deprotection, cleavage, purification (typically using reverse-phase HPLC), and rigorous quality control analysis to ensure high purity and correct sequence integrity. These precision molecules continue to underpin the advancement of nucleic acid therapeutics and personalized medicine approaches. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5182/oligonucleotide-process-development-and-manufacturing-market

What Is the Future of Brachytherapy Afterloaders? Growth Forecasts According to a newly published market research report by 24LifeSciences, global brachytherapy afterloaders market was valued at USD 92.2 million in 2024 and is projected to reach USD 102 million by 2031, growing at a compound annual growth rate (CAGR) of 1.5% during the forecast period 2025-2031. A brachytherapy afterloader is a sophisticated medical device used to deliver targeted internal radiation therapy for cancer treatment. These systems are the technological backbone of modern brachytherapy, automating the precise placement and removal of radioactive sources directly inside or next to tumors. This targeted approach minimizes radiation exposure to healthy surrounding tissues and medical staff while delivering highly concentrated radiation doses to cancerous cells. These devices are critically important in treating prostate, gynecological, breast, and other cancers where precise radiation delivery is essential for optimal patient outcomes. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6426/brachytherapy-afterloaders-market-market-market

Top 10 Companies Leading the Global CAR-NK Cell Development Services According to a newly published market research report by 24LifeSciences, global CAR-NK cell development service market was valued at USD 582 million in 2024 and is projected to reach USD 797 million by 2031, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period 2025-2032. CAR-NK cell development services provide comprehensive solutions for designing, engineering, and optimizing chimeric antigen receptor natural killer cells for therapeutic applications. These services include vector design and construction, cell isolation and expansion, genetic modification and engineering, functional validation and characterization, as well as scale-up and manufacturing support. The market growth is driven by increasing investment in cell and gene therapy research, rising prevalence of hematological malignancies, and growing adoption of off-the-shelf cell therapies. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/4874/car-nk-cell-development-service-market

Hemorrhoids Treatment Market Growth Analysis & Opportunities According to a newly published market research report by 24LifeSciences, global hemorrhoids treatment market was valued at USD 725.8 million in 2024 and is projected to reach USD 1.07 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period 2025–2032. Hemorrhoids, clinically known as piles, are swollen veins in the lower rectum and anus that cause discomfort, itching, and bleeding. The condition affects nearly 50% of the adult population over age 50 and represents a significant healthcare burden globally. Treatment modalities range from over-the-counter topical preparations to advanced minimally invasive procedures like rubber band ligation, sclerotherapy, infrared coagulation, and surgical interventions. The market's growth is primarily driven by increasing prevalence, aging demographics, and technological advancements favoring less invasive treatment options. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10096/hemorrhoids-treatment-market

Global Knee Bursitis Treatment Market Size & Forecast to 2034 According to a newly published market research report by 24LifeSciences, global knee bursitis treatment market was valued at USD 821.4 million in 2024 and is projected to reach USD 1.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period 2024–2031. Knee bursitis involves the inflammation of the small fluid-filled sacs (bursae) that cushion the bones, tendons, and muscles around the knee joint. This painful condition, often developing from repetitive pressure, acute injury, or infection, significantly impairs mobility. Treatment typically combines rest, ice, anti-inflammatory medications, physical therapy, and in severe cases, corticosteroid injections or surgical intervention. The markets expansion reflects the critical need for effective solutions to manage pain and restore function for patients worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9087/knee-bursitis-treatment-market

How Immunotherapy Drives Brain Tumor Therapeutics Market Growth According to a newly published market research report by 24LifeSciences, global brain tumor therapeutics market was valued at USD 1.27 billion in 2025 and is projected to grow from USD 1.41 billion in 2025 to reach USD 2.63 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.3% during the forecast period. Brain tumor therapeutics encompass a comprehensive range of treatments, including surgery, radiation therapy, targeted therapy, chemotherapy, and immunotherapy, all designed to address abnormal cellular growth within the brain. These therapeutic modalities are critical for removing or destroying tumor cells, controlling their proliferation, and managing debilitating symptoms. The choice of treatment strategy is highly individualized, often involving a tailored combination of these approaches based on the specific tumor type, its grade and location, and the patient's overall health status. While surgical intervention remains a foundational element for many primary brain tumors, the ongoing development of novel targeted agents and sophisticated immunotherapies is actively revolutionizing the treatment landscape, offering renewed hope for patients confronting aggressive and recurrent tumor types. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8975/brain-tumor-therapeutics-market

Top 7 Innovations in Targeted Therapy for Malignant Glioma According to a newly published market research report by 24LifeSciences, Global Malignant Glioma Therapeutic Market was valued at USD 4.8 Billion in 2025 and is projected to grow from USD 5.1 billion in 2026 to reach USD 8.2 Billion by 2034, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. Malignant gliomas, particularly glioblastoma multiforme (GBM), represent some of the most aggressive and lethal primary brain tumors. These cancers are characterized by their rapid proliferation, invasive nature, and profound neurological devastation. The standard of care has long involved a multidisciplinary approach including maximal safe surgical resection, radiotherapy, and chemotherapy, with temozolomide serving as the chemotherapeutic backbone. However, the treatment landscape is rapidly evolving beyond these conventional modalities. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9028/malignant-glioma-therapeutic-market

What Is the Future of Solid Tumor Therapeutics? Growth Forecasts According to a newly published market research report by 24LifeSciences, global solid tumor therapeutics market was valued at USD 129.83 billion in 2025 and is projected to grow from USD 141.83 billion in 2026 to reach USD 237.04 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.2% during the forecast period. Solid tumor therapeutics are treatments designed to target and eradicate abnormal masses of tissue that do not contain cysts or liquid areas. These therapies are a cornerstone of oncology, addressing a wide range of cancers that manifest as solid masses, such as those found in the breast, lung, prostate, and colon. The therapeutic landscape includes several key modalities, primarily chemotherapy, hormone therapy, immunotherapy, and targeted therapy, each with distinct mechanisms of action. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9242/solid-tumor-therapeutics-market

Next-Gen Cell Therapy Transforming the Bio-Artificial Pancreas Industry According to a newly published market research report by 24LifeSciences, global Bio-Artificial Pancreas market is valued at USD 425.6 million in 2025 and is projected to grow from USD 489.4 million in 2026 to reach USD 1.2 billion by 2034, growing at a compound annual growth rate (CAGR) of 16.2% during the forecast period. A Bio-Artificial Pancreas is a sophisticated closed-loop system that automates blood glucose management for individuals with diabetes. This innovative medical technology integrates continuous glucose monitoring (CGM) with an insulin pump, utilizing advanced control algorithms to replicate the glucose-regulating functions of a healthy pancreas. The system autonomously administers insulin based on real-time blood sugar readings, substantially reducing the need for manual interventions and significantly improving patient quality of life. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8853/bio-artificial-pancreas-market

Global Heparin Sodium Market Projected to Grow at a CAGR of 6.7% by 2034 According to a newly published market research report by 24LifeSciences, global Heparin Sodium market was valued at USD 2.68 billion in 2026 and is projected to reach USD 4.06 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.7% during the forecast period. Heparin Sodium, derived primarily from porcine intestinal mucosa, is a naturally occurring anticoagulant and a cornerstone therapy for preventing and treating life-threatening thrombotic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes. It functions by potentiating antithrombin III to inactivate key clotting factors, thereby preventing the formation and extension of dangerous blood clots. Its well-established efficacy and immediate onset of action continue to make it indispensable in surgical procedures, dialysis, and critical care settings worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7436/heparin-sodium-market

Hydroxycarbamide Market’s CAGR of 6.1%: Leaders in Oncology & Hematology According to a newly published market research report by 24LifeSciences, global hydroxycarbamide market was valued at USD 226 million in 2025 and is projected to grow from USD 240 million in 2026 to reach USD 338 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Hydroxycarbamide, clinically known as hydroxyurea, is a foundational antineoplastic and antimetabolite medication that functions by inhibiting ribonucleotide reductase, a crucial enzyme for DNA synthesis. This mechanism positions it as a cornerstone therapy for several hematologic conditions. Its primary applications include the management of sickle cell disease, where it significantly reduces the frequency of painful crises and acute chest syndrome, as well as the treatment of specific cancers like chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Its established efficacy in cytoreduction and symptom management continues to underpin its critical importance in hematology and oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/663/hydroxycarbamide-market-market

Top 7 Breakthrough Therapies Transforming Axial Spondyloarthritis Treatment According to a newly published market research report by 24LifeSciences, global axial spondyloarthritis treatment market is valued at USD 4.12 billion in 2026 and is projected to reach USD 7.05 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. Axial spondyloarthritis (axSpA) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing significant pain, stiffness, and potential spinal fusion. Treatment focuses on reducing inflammation, managing symptoms, and preserving mobility through pharmaceutical interventions like NSAIDs, biologic DMARDs (including TNF inhibitors and IL-17 inhibitors), and targeted synthetic DMARDs, supplemented by physiotherapy and lifestyle modifications. The growing understanding of its pathophysiology and the expansion of effective biologic treatments continue to enhance patient outcomes and drive market evolution. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9253/axial-spondyloarthritis-treatment-market